AI/ML Expertise · Case Study

From 27 days to 5.

How Kymera’s Gen-AI transformed pharmaceutical ad compliance — turning a slow, manual MLR review into a fast, reliable, AI-assisted process.

27→5 days review 50–60% lower cost Text · Image · Templates
Talk to us → Explore Kymera
The case

One Gen-AI product, a 5× faster outcome.

PROBLEM

The challenge

  • Pharma ads face delays due to strict compliance rules, making it hard to balance creativity with accuracy.
  • Each company has its own rules for products and branding.
SOLUTION

What Kymera delivers

  • Kymera’s Gen-AI product
  • Flags, explains and fixes problematic claims in 5 days instead of 27
  • Reduces ad review costs by 50–60%
  • Capable of examining text, images and marketing templates
27→0 days to flag, explain & fix claims
0% reduction in ad review costs (50–60%)
3 formats reviewed: text, images & templates
The MLR problem

Teams have learned to work around it rather than fix it.

The review process exists for legitimate reasons — the consequences of a non-compliant asset reaching market range from untitled letters to formal enforcement, reputational damage and costly retroactive corrections. The problem isn’t the requirement. It’s the process:

LATE FLAGS

Review cycles that stretch to four weeks or longer because problematic claims are identified late — after rounds of creative development — rather than flagged where fixing them is still inexpensive.

VERSION CHAOS

Email-based routing and spreadsheet tracking that lose version control, create missed-approval risks, and make it impossible to know which version of an asset is the currently approved one.

MISALLOCATED

Reviewers spending significant time on asset types that should qualify for expedited review — leaving less capacity for the high-risk, high-complexity materials that genuinely need their full attention.

MANUAL ROUTING

Marketing ops manually classifying every asset’s risk level and routing it — a metadata discipline most teams can’t maintain under campaign-volume pressure.

LOCKED WINDOW

Q4 campaigns entering MLR as early as September to allow approval time — compressing the planning window and limiting the ability to respond to market conditions in real time.

INCONSISTENCY

Revision cycles driven by inconsistent interpretation of brand and regulatory standards across reviewers — different feedback on similar assets and multiple rounds of correction before approval.

0 untitled letters · through Q2 2026

The FDA’s renewed enforcement focus has made this worse — disproportionately targeting oncology and weight-loss categories. The risk of a non-compliant asset reaching market is not theoretical, and the organizations absorbing it are the ones whose review processes don’t catch problems early enough to fix them before they become enforcement exposure.

The Kymera solution

Compliance intelligence that works before human review begins.

Kymera flags, explains and resolves problematic claims before materials enter the formal MLR queue — so the time human reviewers spend is concentrated on the decisions that genuinely require their expertise, not the pattern-matching that can be identified earlier.

What it examines
  • Written claimsAcross every asset type — identifying language that is unsupported, misleading, imbalanced, or inconsistent with the approved label.
  • Images & visualsPhotography, graphics and design components reviewed for elements that undermine fair balance or create misleading impressions the copy alone doesn’t address.
  • Marketing templatesValidating that templated frameworks used across campaigns maintain compliance at the template level, not just in individual executions.
What it does
  • FlagsSpecific problematic claims with clear identification of the issue — not a general concern that leaves the creative team guessing what to fix.
  • ExplainsWhy each flagged item presents a risk — connecting it to the specific regulatory standard or brand guideline it conflicts with, so the rationale is understood.
  • CorrectsProposes a specific compliant alternative the creative team can evaluate and adopt — reducing the back-and-forth that drives revision cycles.
RESULT 27 days to 5 · review costs reduced 50–60% · a compliance process that runs at the speed modern omnichannel marketing actually requires.
The results

What 5 days instead of 27 actually changes.

The timeline compression is the headline metric. The downstream effects are where the business case becomes compelling.

50–60% lower review costs

Less work enters formal MLR, revision cycles are shorter, and reviewer time concentrates on the complex, high-risk materials that genuinely require expert judgment.

Fewer revision cycles

Assets arrive at formal review substantially more compliant — so reviewer time is spent on genuine judgment calls, not correcting the same recurring issues.

Consistent standards, every time

Kymera applies the same standards to every asset — eliminating the inconsistency of different reviewers interpreting guidelines differently or fatigue affecting judgment.

How Kymera works

Five steps from upload to a cleaner review.

  1. 01

    Upload the asset

    Any format, any channel — copy, images, templates, digital and HCP materials. Kymera ingests it without manual prep or format conversion.

  2. 02

    Review against your standards

    Checked against your brand guidelines, approved label language and the regulatory standards for the therapeutic area and channel — not generic rules.

  3. 03

    Flag, explain & correct

    Every problematic claim is flagged with a clear explanation and a specific proposed correction — actionable guidance, not a list of concerns.

  4. 04

    Human review of the corrected material

    The asset reaches the MLR queue substantially cleaner, with routine issues resolved and reviewers’ attention free for genuine judgment calls.

  5. 05

    Continuous improvement

    Kymera maps your review patterns over time, improving accuracy with every asset — no manual retraining or configuration updates required.

Who this is for

When review speed is a real constraint on execution.

Kymera is built for pharmaceutical, biotech and medical-device marketing and compliance teams where the speed of promotional review is an active limiter on campaign timing, content volume and the ability to operate competitively in an omnichannel environment.

01

Organizations in high-scrutiny therapeutic areas where enforcement risk is elevated

02

Teams managing high content volumes across digital, social and HCP channels where manual review is a throughput bottleneck

03

Marketing operations teams whose review routing depends on manual risk classification that doesn’t scale with content volume

04

Compliance teams whose reviewers spend time on asset types that could be pre-validated before formal review begins

What it’s costing you

What a 27-day review cycle is actually costing your marketing organization.

The direct cost is in the review infrastructure. The strategic cost — missed windows, frozen timelines, a creative team that stops optimizing early — is larger.

// cost

Review infrastructure

Reviewer time, revision cycles, and the coordination overhead of an email-based routing system never designed for modern omnichannel content volume.

// cost

Missed market windows

A launch delayed by a three-week review cycle is a campaign that missed its window — the strategic cost that dwarfs the operational one.

// cost

Locked-in timelines

A Q4 initiative that entered review in September couldn’t incorporate anything learned from Q3 — the plan was frozen months before launch.

// cost

Early-stage neglect

A creative team that expects revision cycles as the standard outcome stops optimizing for compliance early, knowing it’ll be caught and corrected later anyway.

The organizations whose marketing operates at the speed the market demands are the ones that restructured the process so compliance intelligence does its work before human reviewers are ever asked to do theirs.

Request a demo

See what your review process looks like when it takes 5 days instead of 27.

Request a Kymera demo → Contact us: (425) 307-1234

Frequently Asked Questions

What is Kymera?

Kymera is a compliance intelligence platform purpose-built for pharmaceutical and biotech promotional review — designed to flag, explain, and resolve problematic claims in marketing materials before they enter the formal MLR review queue. It examines written copy, images, and marketing templates against your organization’s specific brand guidelines and regulatory standards, reducing review timelines and revision cycles while improving compliance consistency across the full content pipeline.

What is MLR review in pharmaceutical marketing?

MLR — Medical, Legal, and Regulatory — is the cross-functional review process that every promotional and marketing asset in pharmaceutical, biotech, and medical device organizations must pass before reaching healthcare professionals or patients. All three functions must sign off on materials, ensuring they are medically accurate, legally defensible, and compliant with FDA and applicable global regulatory standards.

How does Kymera reduce review timelines from 27 days to 5?

By resolving the compliance issues that drive revision cycles before materials enter formal MLR review. When the creative team receives specific, actionable feedback on problematic claims — including proposed corrections — before the asset reaches the formal queue, the material arrives substantially cleaner. Reviewers spend their time on genuine judgment calls rather than correcting the same categories of issues that recur across asset types, and the number of review rounds required before approval drops significantly.

What types of content can Kymera review?

Kymera examines written promotional claims across all asset types, images and visual elements, and marketing templates — covering HCP campaign materials, patient support content, digital and social assets, and the templated frameworks used across campaign families.

How does Kymera apply compliance standards consistently?

Kymera applies the same standards to every asset every time — eliminating the inconsistency that occurs when different reviewers interpret guidelines differently or when review volume affects the consistency of judgment. Standards are applied systematically rather than variably, which produces more predictable outcomes for the creative team and fewer surprises in the formal review process.

How does Kymera improve over time?

Kymera maps your organization’s specific review patterns and standards with each asset reviewed, improving the accuracy and relevance of flagging without requiring manual retraining or configuration updates. The platform becomes more precisely calibrated to how your organization applies its specific brand and regulatory standards as it processes more of your content.